Masi Alfonse T, Rehman Azeem A, Jorgenson Laura C, Aldag Jean C
Department of Medicine, University of Illinois College of Medicine at Peoria (UICOMP), Peoria, IL, USA.
Department of Neurosurgery, West Virginia University School of Medicine, Morgantown, WV, USA.
Clin Exp Rheumatol. 2017 Mar-Apr;35(2):277-287. Epub 2016 Oct 26.
This study aimed to critically investigate all-cause and major-cause mortality of incident rheumatoid arthritis (RA) cases versus matched non-RA comparison (CN) subjects in a long-term prospective cohort.
Baseline 1974 cohort entry demographic and serum biomarker data on 54 incident RA patients and 216 matched CN subjects were related to their mortality from 1995 through 2015. Mortality of RA patients was also analysed by 3 categories of course responses to therapy assigned by the sole community rheumatologist in 1995 (19 good, 23 fair, and 12 limited). Cox proportional hazards regression models including baseline covariates were used to determine survival from all-causes, cardiovascular disease (CVD), respiratory-related, malignancies, and other causes of death (CODs).
Total deaths occurred in 38 (70.4 percent) of 54 RA and 102 (47.7 percent) of 216 CN (p=0.003). Total mortality remained greater (p=0.011) in RA versus CN subjects after adjustment for baseline demographic covariates (HR= 1.66, 95% CI 1.12-2.46). Respiratory-related CODs were also greater (p=0.047) in RA versus CN (HR= 2.69, 95% CI 1.02-7.14) subjects. The RA patients' responses to therapy in 1995 significantly (p=0.004) predicted total mortality. Baseline serum immunological and steroid biomarkers independently predicted total, CVD, and other and unknown CODs. Pre-clinical (1974) ranked biomarker z-score values (1 = lowest, 5 = highest) within matched sets of 1 RA and 4 CN study subjects independently associated with mortality from 1995 through 2015, for both total (CRP, p=0.028 and sIL-2Rα, p=0.030) and CVD (CRP, p=0.005 and sTNF-R1, p=0.003) deaths.
Total mortality and respiratory-related CODs were greater in incident RA versus CN subjects. The 35 RA cases who had fair or limited course responses to rheumatologist's therapy had greater mortality than their matched CN, whereas the 19 good RA responders had equivalent survival to CN subjects. The independent CRP and sTNF-R1 biomarker associations with CVD deaths were enhanced by a gradient of their dichotomous z-score values in survival models.
本研究旨在对一个长期前瞻性队列中初发类风湿关节炎(RA)患者与匹配的非RA对照(CN)受试者的全因死亡率和主要死因死亡率进行批判性调查。
1974年队列入组时,收集了54例初发RA患者和216例匹配的CN受试者的基线人口统计学和血清生物标志物数据,并将其与1995年至2015年期间的死亡率相关联。RA患者的死亡率还根据1995年唯一的社区风湿病学家分配的3类治疗反应进行分析(19例良好,23例中等,12例有限)。使用包含基线协变量的Cox比例风险回归模型来确定全因、心血管疾病(CVD)、呼吸相关、恶性肿瘤和其他死因(COD)的生存率。
54例RA患者中有38例(70.4%)死亡,216例CN受试者中有102例(47.7%)死亡(p = 0.003)。在对基线人口统计学协变量进行调整后,RA患者的总死亡率仍然高于CN受试者(p = 0.011)(HR = 1.66,95%CI 1.12 - 2.46)。RA患者中呼吸相关的COD也高于CN受试者(p = 0.047)(HR = 2.69,95%CI 1.02 - 7.14)。1995年RA患者对治疗的反应显著(p = 0.004)预测了总死亡率。基线血清免疫学和类固醇生物标志物独立预测了总死亡率、CVD死亡率以及其他和不明原因的COD。在1例RA和4例CN研究受试者的匹配组中,临床前(1974年)排名的生物标志物z评分值(1 = 最低,5 = 最高)与1995年至2015年期间的死亡率独立相关,包括总死亡率(CRP,p = 0.028和sIL - 2Rα,p = 0.030)和CVD死亡率(CRP,p = 0.005和sTNF - R1,p = 0.003)。
初发RA患者的总死亡率和呼吸相关的COD高于CN受试者。对风湿病学家治疗反应为中等或有限的35例RA患者的死亡率高于其匹配的CN受试者,而19例反应良好的RA患者的生存率与CN受试者相当。在生存模型中,CRP和sTNF - R1生物标志物与CVD死亡的独立关联通过其二分z评分值的梯度得到增强。